Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Senseonics NYSE:SENS$0.46 +0.01 (+1.79%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. More about SenseonicsMarket Capitalization$371.50 millionP/E Ratio-3.51Consensus RatingBuyConsensus Price Target$1.54 (+237.2% Upside)Volume2.94 million sharesAverage Volume8.06 million shares Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. Western Copper & Gold NYSE:WRN$1.52 +0.03 (+2.01%) As of 02:48 PM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$304.84 millionP/E Ratio-76.00Consensus RatingBuyConsensus Price Target$4.00 (+163.2% Upside)Volume157,669 sharesAverage Volume379,863 shares3. Immunic NASDAQ:IMUX$0.76 -0.01 (-1.56%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$74.78 millionP/E Ratio-0.81Consensus RatingBuyConsensus Price Target$7.50 (+889.4% Upside)Volume1.77 million sharesAverage Volume1.25 million shares4. Ur Energy NYSEAMERICAN:URG$1.48 -0.07 (-4.19%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur EnergyMarket Capitalization$538.12 millionP/E Ratio-8.68Consensus RatingBuyConsensus Price Target$2.48 (+66.7% Upside)Volume5.63 million sharesAverage Volume5.48 million shares5. Mereo BioPharma Group NASDAQ:MREO$1.76 +0.04 (+2.02%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More about Mereo BioPharma GroupMarket Capitalization$280.64 millionP/E Ratio-25.21Consensus RatingBuyConsensus Price Target$7.40 (+319.3% Upside)Volume744,710 sharesAverage Volume1.69 million shares6. Stardust Power NASDAQ:SDST$0.30 -0.01 (-2.16%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.Market Capitalization$25.72 millionP/E Ratio-0.54Consensus RatingBuyConsensus Price Target$5.11 (+1,581.7% Upside)Volume976,003 sharesAverage Volume4.21 million shares7. Plus Therapeutics NASDAQ:PSTV$0.48 +0.03 (+6.52%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. More about Plus TherapeuticsMarket Capitalization$47.55 millionP/E Ratio-0.21Consensus RatingBuyConsensus Price Target$7.88 (+1,544.1% Upside)Volume4.31 million sharesAverage Volume18.68 million shares8. zSpace NASDAQ:ZSPC$1.64 -0.09 (-5.20%) As of 02:52 PM EasternzSpace Technologies, Inc is a provider of commercial augmented reality and virtual reality technology principally in the education market. More about zSpaceMarket Capitalization$39.43 millionConsensus RatingBuyConsensus Price Target$10.00 (+509.8% Upside)Volume75,643 sharesAverage Volume72,700 sharesToday's Range$1.60▼$1.809. Quince Therapeutics NASDAQ:QNCX$1.61 +0.01 (+0.31%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$86.47 millionP/E Ratio-1.48Consensus RatingBuyConsensus Price Target$8.14 (+405.8% Upside)Volume70,418 sharesAverage Volume228,338 shares10. Ovid Therapeutics NASDAQ:OVID$1.20 -0.09 (-6.98%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid TherapeuticsMarket Capitalization$85.69 millionP/E Ratio-2.27Consensus RatingBuyConsensus Price Target$3.10 (+158.3% Upside)Volume1.02 million sharesAverage Volume1.01 million shares11. Biomea Fusion NASDAQ:BMEA$1.92 +0.09 (+4.64%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More about Biomea FusionMarket Capitalization$113.96 millionP/E Ratio-0.63Consensus RatingBuyConsensus Price Target$14.80 (+672.8% Upside)Volume429,218 sharesAverage Volume1.32 million shares12. Context Therapeutics NASDAQ:CNTX$0.82 -0.01 (-0.86%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$73.64 millionP/E Ratio-2.28Consensus RatingBuyConsensus Price Target$5.25 (+539.5% Upside)Volume49,612 sharesAverage Volume195,918 shares13. Reviva Pharmaceuticals NASDAQ:RVPH$0.44 0.00 (-1.07%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$29.99 millionP/E Ratio-0.68Consensus RatingBuyConsensus Price Target$5.20 (+1,076.5% Upside)Volume462,669 sharesAverage Volume1.68 million shares14. TScan Therapeutics NASDAQ:TCRX$1.88 -0.01 (-0.53%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. More about TScan TherapeuticsMarket Capitalization$107.82 millionP/E Ratio-1.74Consensus RatingBuyConsensus Price Target$7.80 (+314.9% Upside)Volume191,393 sharesAverage Volume448,334 shares15. Tenaya Therapeutics NASDAQ:TNYA$1.34 +0.11 (+8.47%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya TherapeuticsMarket Capitalization$219.21 millionP/E Ratio-1.40Consensus RatingBuyConsensus Price Target$6.25 (+364.7% Upside)Volume3.91 million sharesAverage Volume2.97 million shares16. IceCure Medical NASDAQ:ICCM$1.03 -0.03 (-2.36%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. More about IceCure MedicalMarket Capitalization$60.75 millionP/E Ratio-6.47Consensus RatingBuyConsensus Price Target$2.39 (+130.4% Upside)Volume899,062 sharesAverage Volume785,009 shares17. Gain Therapeutics NASDAQ:GANX$1.76 +0.02 (+1.15%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain TherapeuticsMarket Capitalization$63.27 millionP/E Ratio-2.79Consensus RatingBuyConsensus Price Target$7.80 (+343.2% Upside)Volume464,464 sharesAverage Volume297,721 shares18. Adicet Bio NASDAQ:ACET$0.72 +0.01 (+1.09%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. More about Adicet BioMarket Capitalization$60.02 millionP/E Ratio-0.55Consensus RatingBuyConsensus Price Target$6.00 (+732.2% Upside)Volume275,340 sharesAverage Volume624,423 shares19. Lucid Diagnostics NASDAQ:LUCD$1.40 +0.03 (+1.81%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$152.41 millionP/E Ratio-1.18Consensus RatingBuyConsensus Price Target$3.65 (+159.8% Upside)Volume2.30 million sharesAverage Volume998,283 shares20. Acrivon Therapeutics NASDAQ:ACRV$1.34 +0.04 (+3.08%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. More about Acrivon TherapeuticsMarket Capitalization$42.16 millionP/E Ratio-0.60Consensus RatingBuyConsensus Price Target$17.57 (+1,211.3% Upside)Volume97,665 sharesAverage Volume398,367 shares21. Bitfarms NASDAQ:BITF$1.28 +0.04 (+2.80%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bitfarms Ltd. engages in the mining of cryptocurrency coins and tokens in Canada, the United States, Paraguay, and Argentina. More about BitfarmsMarket Capitalization$714.65 millionP/E Ratio-7.56Consensus RatingBuyConsensus Price Target$3.95 (+207.4% Upside)Volume14.64 million sharesAverage Volume25.77 million shares22. Autolus Therapeutics NASDAQ:AUTL$1.44 -0.02 (-1.03%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus TherapeuticsMarket Capitalization$381.91 millionP/E Ratio-1.71Consensus RatingBuyConsensus Price Target$9.12 (+535.5% Upside)Volume7.66 million sharesAverage Volume2.00 million shares23. Werewolf Therapeutics NASDAQ:HOWL$1.36 +0.01 (+0.37%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. More about Werewolf TherapeuticsMarket Capitalization$61.96 millionP/E Ratio-0.83Consensus RatingBuyConsensus Price Target$8.00 (+490.4% Upside)Volume96,304 sharesAverage Volume345,879 shares24. Ceragon Networks NASDAQ:CRNT$1.98 -0.03 (-1.24%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ceragon Networks Ltd., together with its subsidiaries, provides wireless transport solutions for cellular operators and other wireless service providers in North America, Europe, Africa, the Asia Pacific, the Middle East, India, and Latin America. More about Ceragon NetworksMarket Capitalization$176.53 millionP/E Ratio12.41Consensus RatingBuyConsensus Price Target$5.30 (+167.0% Upside)Volume190,622 sharesAverage Volume1.27 million shares25. Humacyte NASDAQ:HUMA$1.44 -0.03 (-1.71%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. More about HumacyteMarket Capitalization$227.26 millionP/E Ratio-3.19Consensus RatingBuyConsensus Price Target$9.75 (+579.4% Upside)Volume1.75 million sharesAverage Volume3.97 million shares More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
